Reduction of blood platelet monoamine oxidase activity in schizophrenic patients on phenothiazines

Folia Psychiatrica Et Neurologica Japonica
|January 1, 1975
PubMed

Insights

Blood platelet monoamine oxidase (MAO) activity was measured in schizophrenic patients. Untreated patients showed no significant MAO reduction, suggesting MAO levels are not linked to schizophrenia diagnosis.

Area of Science:

  • Neuroscience
  • Biochemistry

Background:

  • Monoamine oxidase (MAO) plays a crucial role in neurotransmitter metabolism.
  • Altered MAO activity has been implicated in various psychiatric disorders.

Purpose of the Study:

  • To investigate blood platelet monoamine oxidase (MAO) activity in schizophrenic patients.
  • To determine if MAO activity is associated with schizophrenia diagnosis or treatment.

Main Methods:

  • A newly developed assay was used to measure MAO activity in blood platelets using serotonin as a substrate.
  • MAO activity was assessed in 76 schizophrenic patients (33 untreated) and compared to normal controls.

Main Results:

  • No significant reduction in blood platelet MAO activity was observed in untreated schizophrenic patients compared to controls.
  • Male schizophrenic patients exhibited lower MAO activity than females, consistent with findings in normal subjects.
  • Phenothiazine treatment significantly reduced platelet MAO activity, without affecting platelet serotonin content or count.

Conclusions:

  • Blood platelet MAO activity does not appear to be directly related to the psychiatric diagnosis of schizophrenia.
  • MAO activity may be influenced by hormonal factors rather than a predisposition to schizophrenia.
  • Phenothiazine treatment impacts MAO activity, highlighting a potential therapeutic mechanism.

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...